Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHIT1 | Q13231 | 13/20 | 0.62 |
| ▸ | CHIA | Q9BZP6 | 13/20 | 0.62 |
| ▸ | CHI3L1 | P36222 | 9/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.49 |
| ▸ | CHI3L2 | Q15782 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18609561 | 1.00 | CHIT1 (0.62) | CHIT1CHIACHI3L1KCNH2CHI3L2 | |
| SCHEMBL18589341 | 1.00 | CHIT1 (0.62) | CHIT1CHIACHI3L1KCNH2CHI3L2 | |
| SCHEMBL18577414 | 1.00 | CHIT1 (0.62) | CHIT1CHIACHI3L1KCNH2CHI3L2 | |
| SCHEMBL22903696 | 0.92 | KCNH2 (0.58) | CHIT1CHIACHI3L1KCNH2CHI3L2 | |
| SCHEMBL26439042 | 0.92 | KCNH2 (0.58) | CHIT1CHIACHI3L1KCNH2CHI3L2 | |
| SCHEMBL18589446 | 0.91 | KCNH2 (0.60) | CHIT1CHIACHI3L1KCNH2CHI3L2 | |
| SCHEMBL18609562 | 0.91 | KCNH2 (0.60) | CHIT1CHIACHI3L1KCNH2CHI3L2 | |
| SCHEMBL18577155 | 0.91 | KCNH2 (0.60) | CHIT1CHIACHI3L1KCNH2CHI3L2 | |
| SCHEMBL26439359 | 0.91 | CHIT1 (0.51) | CHIT1CHIACHI3L1KCNH2 | |
| SCHEMBL23169723 | 0.90 | CHIA (0.58) | CHIT1CHIACHI3L1KCNH2CHI3L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190345137-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | GALAPAGOS NV (BE) | 2019-11-14 | — | — | US | disclosed |
| US-10208020-B2 | Substituted amino triazoles useful as human chitinase inhibitors | Oncoarendi Therapeutics S.A. (PL) | 2019-02-19 | — | — | US | disclosed |
| EP-3344616-B1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | ONCOARENDI THERAPEUTICS SA (PL) | 2019-01-09 | — | — | EP | disclosed |
| US-9944624-B2 | Substituted amino triazoles useful as human chitinase inhibitors | Oncoarendi Therapeutics S.A. (PL) | 2018-04-17 | — | — | US | disclosed |
| US-20170066743-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | GALAPAGOS NV (BE) | 2017-03-09 | — | — | US | disclosed |
| WO-2017037670-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | OncoArendi Therapeutics Sp. z o.o. (PL) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345137-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | CHIA, CHIT1, AADAC | CHIT1 2/4885CHIA 1/4885CHI3L1 4/4885 |
| US-10208020-B2 | Substituted amino triazoles useful as human chitinase inhibitors | CHIA, CHIT1, AADAC | CHIT1 2/4885CHIA 1/4885CHI3L1 4/4885 |
| US-20170066743-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | CHIA, CHIT1, AADAC | CHIT1 2/4885CHIA 1/4885CHI3L1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.